U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Sewaren Innovative Pharmaceutical Packaging dba SIPP - 513186 - 02/01/2018
  1. Warning Letters

CLOSEOUT LETTER

Sewaren Innovative Pharmaceutical Packaging dba SIPP MARCS-CMS 513186 —

Recipient:
Sewaren Innovative Pharmaceutical Packaging dba SIPP

United States

Issuing Office:

United States

 

   

Black HHS-Blue FDA Logo

 

Division of Pharmaceutical Quality Operations I
10 Waterview Blvd, 3rd FL
Parsippany, NJ 07054
Telephone: (973) 331-4900
Fax: (973) 331-4969
 
 

February 1, 2018

VIA UPS NEXT DAY AIR

Hank Incognito, Owner
Sewaren Innovative Pharmaceutical Packaging dba SIPP
994 Rahway Avenue Suite 1
Avenel, NJ 07001-1946

Dear Mr. Incognito:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s May 31, 2017 response to our warning letter WL # 17-NWJ-02 dated May 22, 2017. We acknowledge that your firm ceased drug production at this facility.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/

Diana Amador Toro
Division Director/OPQ Division 1
New Jersey District Office 

Back to Top